RAPIDOSE

Cover Block

Name	RAPIDOSE
Tagline	Medical device for accurate, weight-based adrenaline dosing in pediatric cardiac arrest.
Headquarters	Auckland, New Zealand
Founded	2024
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Growth Profile	Venture Scale
Founding Team	Adrian Ng [LinkedIn, 2026]
Funding Label	Pre-Seed
Total Disclosed	Amount undisclosed [NZ Herald, 2026]

Links

• Website: https://www.auckland.ac.nz/en/news/2025/08/25/latest-start-ups-emerging-from-the-universitys-incubator.html
• LinkedIn: https://www.linkedin.com/company/rapidose

Summary and Signal

RAPIDOSE is developing a medical device to standardize weight-based adrenaline dosing for children in cardiac arrest, a clinical scenario where speed and precision are critical [University of Auckland, Aug 2025]. Founded in 2024, the company has secured pre-seed backing from Icehouse Ventures and Outset Ventures, the latter of which hosts the startup in its accelerator program [NZ Herald, 2026]. The device was developed in collaboration with frontline healthcare providers [Prospeo]. Founder Adrian Ng leads the venture. As a hardware play in regulated medical technology, the company's path forward hinges on securing regulatory approvals, initiating clinical validation, and establishing commercial deployments. Over the next 12 to 18 months, primary signals for investors will be progress toward these regulatory and clinical gates, alongside pilot partnerships with hospital systems.

Data Accuracy: YELLOW -- Core company facts and investor names are confirmed; product claims are sourced from the company and affiliated university. Team details and commercial progress are limited.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Growth Profile	Venture Scale

Company Overview

RAPIDOSE is a hardware-focused healthtech venture founded in Auckland, New Zealand, in 2024. The company's public emergence is documented through a University of Auckland incubator profile from August 2025, which describes the development of an innovative medical device for pediatric cardiac arrest [University of Auckland, Aug 2025].

The company's primary milestone to date is securing pre-seed funding from New Zealand-based venture firms Icehouse Ventures and Outset Ventures, with the latter also serving as an accelerator program [NZ Herald, 2026].

Data Accuracy: YELLOW -- Company founding and funding confirmed by multiple sources; specific founder details and corporate milestones are limited.

The Product and the Stack

RAPIDOSE is a single-purpose medical device designed to ensure accurate, weight-based adrenaline dosing for children in cardiac arrest [University of Auckland, Aug 2025]. The company's public positioning centers on this core function, framing the device as a tool to reduce dosage errors and improve speed in a critical clinical scenario.

Descriptions suggest the device was developed in collaboration with frontline healthcare providers [Prospeo]. The technology stack is not publicly detailed, but the device's purpose implies integration of hardware for dose measurement and delivery, potentially with software for weight-based calculation.

Data Accuracy: YELLOW -- Product claims are consistent across two sources, but technical specifications and regulatory status are unconfirmed.

The Market They Are Entering

The market for pediatric emergency medical devices is defined by a persistent clinical need for speed and precision. Quantitative market sizing for a device like RAPIDOSE is not publicly disclosed. For context, the global market for emergency medical devices was valued at approximately $27.5 billion in 2023 [Grand View Research, 2024]. The pediatric medical device segment faces well-documented challenges, including a smaller patient population and high development costs, but is an area of significant unmet need [FDA, 2023].

Demand for a solution like RAPIDOSE is anchored in two primary clinical drivers. First, pediatric cardiac arrest protocols require weight-based dosing of medications like epinephrine, where manual calculations under time pressure are a known source of error [Pediatrics, 2022]. Second, the trend towards digitization and automation in clinical workflows creates a tailwind for devices that integrate decision support directly into the point of care.

Regulatory pathways present a defining macro force. As a medical device claiming to improve dosing accuracy, RAPIDOSE would require regulatory clearance, such as a CE Mark or FDA 510(k) clearance. The process is lengthy, costly, and requires clinical validation data.

Metric	Value
Emergency Medical Devices (Global, 2023)	$27.5B

Data Accuracy: YELLOW -- Market sizing is based on an analogous, broad sector report. Specific demand drivers are supported by general clinical literature, but no company-specific market analysis is publicly available.

The Competitive Field

RAPIDOSE enters a medical device niche where competition is defined by incumbent distributors, established emergency equipment manufacturers, and the pervasive alternative of manual calculation.

Company	Positioning	Stage / Funding	Notable Differentiator
RAPIDOSE	Pediatric-specific, weight-based adrenaline dosing device for cardiac arrest.	Pre-Seed. Backed by Icehouse Ventures and Outset Ventures.	Focus on pediatric dosing accuracy and clinician co-development.
Device Technologies NZ	National distributor of a wide range of medical devices.	Private, established distributor.	Broad portfolio and existing hospital supply relationships.
Amtech Medical	New Zealand-based manufacturer and distributor of medical devices.	Private, established manufacturer.	Local manufacturing capability and regulatory familiarity.
Obex	Manufacturer of medical and laboratory equipment.	Private, established manufacturer.	Adjacent product lines in the emergency care workflow.

Data Accuracy: YELLOW -- Competitor profiles are confirmed via company websites, but RAPIDOSE's differentiation and market position are inferred from limited public claims.

Opportunity

The prize for RAPIDOSE is a position as the standard of care for pediatric resuscitation, a role that would command both a premium price and a recurring revenue stream. The headline opportunity is to become the default, hardware-enabled dosing standard for pediatric advanced life support (PALS) in hospital emergency departments and critical care units.

Scenario	What happens	Catalyst
Regulatory Standard Capture	National or international pediatric resuscitation guidelines are updated to recommend or require weight-based dosing devices.	Publication of a pivotal clinical trial demonstrating RAPIDOSE reduces dosing errors and improves outcomes.
Health System Land-and-Expand	A major national or regional health system adopts RAPIDOSE across all its pediatric emergency and ICU sites.	A procurement deal with a large public or private hospital network.
Integration as a Platform Anchor	RAPIDOSE becomes the hardware component of a broader emergency response software platform.	A partnership with an established electronic health record (EHR) vendor or EMS software provider.

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated value proposition and analogous market dynamics; specific traction, regulatory milestones, or partnership details are not yet publicly confirmed.

Sources

1. [University of Auckland, Aug 2025] The latest start-ups emerging from the University’s incubator | https://www.auckland.ac.nz/en/news/2025/08/25/latest-start-ups-emerging-from-the-universitys-incubator.html
2. [NZ Herald, 2026] RAPIDOSE funding and accelerator participation | https://www.nzherald.co.nz/business/rapidose-icehouse-ventures-outset-ventures-funding-2026
3. [LinkedIn, 2026] Adrian Ng - Founder - RapiDose | https://nz.linkedin.com/in/ang775
4. [Prospeo] RAPIDOSE - pediatric adrenaline dosing device (emergency medicine) | https://prospeo.io/c/rapidose
5. [Device Technologies NZ, 2026] Device Technologies NZ company profile | https://www.devicetechnologies.co.nz
6. [Amtech Medical, 2026] Amtech Medical company profile | https://www.amtechmedical.co.nz
7. [Obex, 2026] Obex Medical company profile | https://www.obex.co.nz
8. [Grand View Research, 2024] Emergency Medical Devices Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/emergency-medical-devices-market
9. [FDA, 2023] Pediatric Medical Devices | https://www.fda.gov/medical-devices/products-and-medical-procedures/pediatric-medical-devices
10. [Pediatrics, 2022] Medication Dosing Errors in Pediatric Resuscitation | https://publications.aap.org/pediatrics/article/150/3/e2021056000/188717/Medication-Dosing-Errors-in-Pediatric-Resuscitation
11. [Various financial reports, 2021] Stryker acquisition of Zoll Medical temperature management business | https://investors.stryker.com/press-releases/news-details/2021/Stryker-to-Acquire-Temperature-Management-Business-from-ZOLL-Medical-Corporation/default.aspx